These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1524906)

  • 1. Phase II study of 5-fluorouracil plus leucovorin and interferon alpha 2b in advanced colorectal cancer.
    Sobrero A; Nobile MT; Guglielmi A; Mori A; Aschele C; Bolli E; Tixi L; Gallo L; Parodi GC; Bruzzi P
    Eur J Cancer; 1992; 28A(4-5):850-2. PubMed ID: 1524906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.
    Steger GG; Mader RM; Djavanmard MP; Gnant MF; Locker G; Marosi C; Rainer H; Jakesz R
    J Cancer Res Clin Oncol; 1994; 120(5):314-8. PubMed ID: 8126062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    Tournigand C; Louvet C; de Gramont A; Lucchi E; Seitz JF; Mal F; Raymond E; Cady J; Carola E; Krulik M
    Cancer; 1997 Mar; 79(6):1094-9. PubMed ID: 9070485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study.
    Punt CJ; Burghouts JT; Croles JJ; van Liessum PA; de Mulder PH; Kamm Y
    Cancer; 1993 Oct; 72(7):2107-11. PubMed ID: 8374869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
    Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ
    J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council.
    Seymour MT; Slevin ML; Kerr DJ; Cunningham D; James RD; Ledermann JA; Perren TJ; McAdam WA; Harper PG; Neoptolemos JP; Nicholson M; Duffy AM; Stephens RJ; Stenning SP; Taylor I
    J Clin Oncol; 1996 Aug; 14(8):2280-8. PubMed ID: 8708718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma.
    Cascinu S; Del Ferro E; Ligi M; Catalano G
    Anticancer Drugs; 1996 Jul; 7(5):520-4. PubMed ID: 8862717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
    J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-alpha 2b and folinic acid. The "GISCAD" experience. Italian Group for the Study of Digestive Tract Cancer.
    Labianca R; Giaccon G; Barni S; Ambrosini G; Iirillo A; Fiorentini G; Duro M; Piazza E; Oliani C; Pancera G
    Eur J Cancer; 1994; 30A(11):1611-6. PubMed ID: 7833131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer.
    Recchia F; Nuzzo A; Lalli A; Lombardo M; Di Lullo L; Fabiani F; Fanini R; Venturoni L; Torchio P; Peretti G
    Am J Clin Oncol; 1996 Jun; 19(3):301-4. PubMed ID: 8638546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients.
    Brunetti I; Falcone A; Bertuccelli M; Cianci C; Ricci S; Conte PF
    Am J Clin Oncol; 1994 Jun; 17(3):210-4. PubMed ID: 8192103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study.
    Punt CJ; de Mulder PH; Burghouts JT; Wagener DJ
    Cancer Chemother Pharmacol; 1992; 29(4):326-8. PubMed ID: 1537082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin.
    Sinnige HA; Buter J; de Vries EG; Uges DR; Roenhorst HW; Verschueren RC; Sleijfer DT; Willemse PH; Mulder NH
    Eur J Cancer; 1993; 29A(12):1715-20. PubMed ID: 8398300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration.
    Buter J; Sinnige HA; Sleijfer DT; de Vries EG; Willemse PH; van der Graaf WT; Verschueren RC; Mulder NH
    Cancer; 1995 Mar; 75(5):1072-6. PubMed ID: 7850703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.
    Hausmaninger H; Moser R; Samonigg H; Mlineritsch B; Schmidt H; Pecherstorfer M; Fridrik M; Kopf C; Nitsche D; Kaider A; Ludwig H
    Eur J Cancer; 1999 Mar; 35(3):380-5. PubMed ID: 10448286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.
    Buroker TR; O'Connell MJ; Wieand HS; Krook JE; Gerstner JB; Mailliard JA; Schaefer PL; Levitt R; Kardinal CG; Gesme DH
    J Clin Oncol; 1994 Jan; 12(1):14-20. PubMed ID: 7677801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose alpha-2b interferon + folinic acid in the modulation of 5-fluorouracil. A phase II study in advanced colorectal cancer with evidence of an unfavourable cost/benefit ratio.
    Labianca R; Pancera G; Tedeschi L; Dallavalle G; Luporini A; Luporini G
    Tumori; 1992 Feb; 78(1):32-4. PubMed ID: 1609456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
    Seymour MT; Johnson PW; Hall MR; Wrigley PF; Slevin ML
    Br J Cancer; 1994 Oct; 70(4):719-23. PubMed ID: 7917927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
    Guglielmi A; Aschele C; Grossi F; Tixi L; Sobrero A
    Cytotechnology; 1996; 19(3):215-9. PubMed ID: 8862009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of high dose 24 hour 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer.
    Nobile MT; Barzacch MC; Sanguineti O; Chiara S; Gozza A; Vincenti M; Lavarello A; Cognein P; Lionetto R; Percivale PL; Bertoglio S; Murolo C; Esposito M; Vannozzi MO; Rosso R
    Anticancer Res; 1998; 18(1B):517-21. PubMed ID: 9568171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.